Cardinal Health's Trading Volume Plummets 31% After February Surge Ranks 379th in Market Activity

Market Snapshot

On March 13, 2026, Cardinal Health (CAH) traded with a volume of $0.31 billion, marking a 31% decline from the prior day’s activity. The stock closed down 0.92%, ranking 379th in trading volume among listed equities. This performance followed a recent surge in early February when shares jumped 9.8% after the company reported Q2 2026 results exceeding expectations. However, the latest dip reflects broader market dynamics and mixed signals from the company’s recent financial updates.

Key Drivers

Cardinal Health’s stock performance in early March 2026 was shaped by a combination of earnings volatility, strategic guidance, and shifting institutional sentiment. The company’s Q2 2026 results, released in February, demonstrated robust growth, with revenue rising 18.8% year-over-year to $65.63 billion and adjusted earnings per share (EPS) surging 36% to $2.63, surpassing the $2.31 consensus estimate. This outperformance, coupled with a 13–15% growth projection for FY2026, initially buoyed investor confidence. However, the subsequent decline in March suggests underlying concerns about sustainability, particularly after the Q4 2025 report revealed a revenue shortfall despite a 13.85% EPS beat.

Strategic initiatives, including acquisitions like Solaris Health and new product launches, underscored the company’s innovation focus. Management highlighted a 19% operating earnings increase to $719 million in Q2 2026 and projected 11–13% growth in its pharmaceutical segment. These moves align with broader industry trends toward healthcare supply chain optimization and specialty drug distribution. Nevertheless, the stock’s 2.4% drop following the Q2 results—despite strong numbers—indicates skepticism about near-term execution risks, particularly in a competitive landscape featuring rivals like McKesson Corporation.

Analyst sentiment further complicated the stock’s trajectory. While Cardinal Health maintained a “Moderate Buy” consensus with an average price target of $245.67, the spread of recommendations reflected divergent views. UBS Group and Jefferies raised price targets to $260 and $270, respectively, citing long-term growth potential, while others like Wall Street Zen downgraded from “Strong Buy” to “Buy.” The Zacks Rank #2 (Buy) rating, supported by a 15% long-term earnings growth estimate, contrasted with Swiss National Bank’s 5.9% stake reduction in Q3 2025, signaling caution among institutional investors.

A dividend announcement added a layer of stability, with Cardinal Health declaring a $0.5107 quarterly payout (0.9% yield). While this reinforced the company’s commitment to shareholder returns, the payout ratio of 29.35% suggests room for growth without overextending cash flow. Analysts noted that the dividend, combined with a market cap of $51.6 billion, positions CAH as a defensive play in a volatile market, though its beta of 0.65 indicates lower volatility compared to the broader market.

Finally, the stock’s relative performance against benchmarks and peers highlighted its mixed appeal. Over the past three months, CAH outperformed the Dow Jones Industrials Average (up 11% vs. the Dow’s 3.7% decline) and surged 74.2% over 52 weeks compared to the Dow’s 12.9% gain. However, rival McKesson’s 15.1% year-to-date outperformance and 47.4% 52-week rally underscored competitive pressures. These dynamics suggest that while Cardinal Health’s fundamentals remain strong, its ability to sustain momentum will depend on navigating macroeconomic headwinds and maintaining its edge in healthcare logistics innovation.